LEADER 04476nam 2200517 450 001 9910137117303321 005 20170817211242.0 010 $a0-323-39566-X 035 $a(CKB)3710000000776375 035 $a(EBL)4621009 035 $a(OCoLC)956278046 035 $a(MiAaPQ)EBC4621009 035 $a(EXLCZ)993710000000776375 100 $a20160826h20152015 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $2rdacontent 182 $2rdamedia 183 $2rdacarrier 200 10$aManagement of Helicobacter pylori-related diseases /$fAkiko Shiotani, David Y. Graham 210 1$aPhiladelphia, Pennsylvania :$cElsevier,$d2015. 210 4$dİ2015 215 $a1 online resource (246 p.) 225 1 $aGastroenterology Clinics of North America,$x0889-8553 ;$vVolume 44, Number 3 300 $a"Clinics Review Articles." 311 $a0-323-39565-1 320 $aIncludes bibliographical references at the end of each chapters and index. 327 $aCover image; Title page; Table of Contents; Copyright Page; Contributors; Consulting Editor; Editors; Authors; Forthcoming Issues; Forthcoming Issues; Recent Issues; Foreword: Helicobacter pylori; Preface: Helicobacter pylori: New Thoughts and Practices; Diagnosis of Helicobacter pylori Infection in the Proton Pump Inhibitor Era; Key points; Introduction; Invasive tests; Serology; Summary: diagnosis of Helicobacter pylori infection in the proton pump inhibitors era; Practical Aspects in Choosing a Helicobacter pylori Therapy; Key points; Introduction; Choice of therapy; First-line regimens 327 $aRescue therapyProbiotics; Summary; How to Effectively Use Bismuth Quadruple Therapy; Key points; Background; Bismuth in the era of new concepts regarding pathogenesis and treatment of peptic ulcer; Bismuth quadruple therapy for H pylori eradication; The effect of metronidazole resistance as examined by meta-analysis; Calculation of the effectiveness of bismuth quadruple therapy; Adherence (compliance) with bismuth quadruple therapy; How to make bismuth quadruple therapy more acceptable; Doxycycline 327 $aExamination of outcome in regions where bismuth quadruple therapy frequently fails (eg, Turkey and Iran)Bismuth, tetracycline, amoxicillin, proton pump inhibitors quadruple therapy; Bismuth sequential therapies; Information needed to obtain generalizable results; Issues ripe for systematic study; Proton pump inhibitors dosage; Efficient study design; Recommendations; Is There a Role for Probiotics in Helicobacter pylori Therapy?; Key points; What probiotics are; Probiotics; Probiotics as adjuvant therapy for Helicobacter pylori eradication; Probiotics as cure for Helicobacter pylori infection 327 $aSummaryMolecular Approaches to Identify Helicobacter pylori Antimicrobial Resistance; Key points; Molecular determination of Helicobacter pylori resistance to macrolides; Molecular determination of Helicobacter pylori resistance to fluoroquinolones; Molecular determination of Helicobacter pylori resistance to tetracycline; Molecular determination of Helicobacter pylori resistance to other antibiotics; When Is Endoscopic Follow-up Appropriate After Helicobacter pylori Eradication Therapy?; Key points; Introduction; Helicobacter pylori eradication; Uninvestigated and nonulcer dyspepsia 327 $aPeptic ulcerPremalignant gastric lesions and early gastric cancer; Hereditary risk for gastric cancer; Mucosa-associated lymphoid tissue lymphoma; Summary; Gastric Cancer Risk in Patients with Helicobacter pylori Infection and Following Its Eradication; Key points; Introduction; Helicobacter pylori infection is the most important determinant of gastric cancer risk; Gastric cancer risk: epidemiologic trends; Gastric cancer risk: the assessment; Gastric cancer risk in eradicated patients; Summary; Molecular Pathogenesis of Helicobacter pylori-Related Gastric Cancer; Key points; Introduction 327 $aClassifications and characterizations of gastric cancer 410 0$aGastroenterology clinics of North America ;$vVolume 44, Number 3. 606 $aHelicobacter pylori 615 0$aHelicobacter pylori. 676 $a579.34 700 $aShiotani$b Akiko$01370376 702 $aGraham$b David Y. 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910137117303321 996 $aManagement of Helicobacter pylori-related diseases$93398677 997 $aUNINA LEADER 01933oam 2200325 a 450 001 9910703222703321 005 20120313143243.0 035 $a(CKB)4950000000097168 035 $a(OCoLC)768762270 035 $a(EXLCZ)994950000000097168 100 $a20111219d2011 ua 0 101 0 $aeng 135 $aurbn||||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aProviding for consideration of the conference report to accompany the bill (H.R. 1540) to authorize appropriations for fiscal year 2012 for military activities of the Department of Defense, for military construction, and for defense activities of the Department of Energy, to prescribe military personnel strengths for such fiscal year, and for other purposes; and providing for proceedings during the period from December 16, 2011, through January 16, 2012$b[electronic resource] $ereport (to accompany H. Res. 493) 210 1$a[Washington, D.C.] :$c[U.S. G.P.O.],$d[2011] 215 $a1 online resource (2 pages) 225 1 $aReport / 112th Congress, 1st session, House of Representatives ;$v112-330 300 $aTitle from title screen (viewed on Dec. 19, 2011). 300 $a"December 13, 2011." 517 $aPROVIDING FOR CONSIDERATION OF THE CONFERENCE REPORT TO ACCOMPANY THE BILL 801 0$bGPO 801 1$bGPO 801 2$bGPO 906 $aBOOK 912 $a9910703222703321 996 $aProviding for consideration of the conference report to accompany the bill (H.R. 1540) to authorize appropriations for fiscal year 2012 for military activities of the Department of Defense, for military construction, and for defense activities of the Department of Energy, to prescribe military personnel strengths for such fiscal year, and for other purposes; and providing for proceedings during the period from December 16, 2011, through January 16, 2012$93454971 997 $aUNINA